IRCT20210612051548N1尚未招募2 期
Targeted a-Therapy in Metastatic Castration Resistant Prostate Cancer with 225Ac-PSMA-617
Boushehr University of Medical Sciences0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- Male
入选标准
- •Patients must have had progressive metastatic castration-resistant prostate cancer.
- •Patients must have a positive 68Ga-PSMA-11 PET/CT scan.
- •Patients must have recovered or stabilized to = Grade 2 from all clinically significant toxicities related to prior prostate cancer therapy.
- •Patients must have an ECOG performance status of 0 to 2.
排除标准
- •Previous treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 or hemi-body irradiation or previous PSMA-targeted radioligand therapy.
- •The patient was diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment (Patients with a prior history of malignancy who have been disease-free for more than 3 years are eligible).
研究者
相似试验
招募中
2 期
Treatment of patients with castration-resistant metastatic prostate cancer with nuclear medicine procedureCastration resistant metastatic prostate cancer.Malignant neoplasm of prostateIRCT20180113038331N1Mashhad University of Medical Sciences20
进行中（未招募）
1 期
To investigate safety and effectiveness of PSMA directed [177-Lu]-PNT2002, an investigational agent for treatment of patients with mCRPCEUCTR2021-002641-15-SEPoint BioPharma Inc.390
招募中
3 期
SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu- PNT2002 PSMA Therapy After Second-line Hormonal Treatment10027655prostate cancerNL-OMON54469POINT BioPharma,30
进行中（未招募）
1 期
To investigate safety and effectiveness of PSMA directed [177-Lu]-PNT2002, an investigational agent for treatment of patients with mCRPCMetastatic Castrate Resistant Prostate Cancer (mCRPC)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002641-15-NLPoint BioPharma Inc.390
进行中（未招募）
不适用
Metastasis-directed Therapy in Castration-refractory Prostate CancerCastration-resistant Prostate CancerNCT04222634Universitaire Ziekenhuizen KU Leuven18